Neutralizing and Infection-Enhancing Antibody Responses Do Not Correlate with the Differential Pathogenicity of SIVmac239Δ3 in Adult and Infant Rhesus Monkeys

Journal of Immunology

Volumn 157, Issue 12, 1996, Pages 5528-5535

  Montefiori, David C ^a   Baba, Timothy W ^b,c   Li, An ^c   Bilska, Miroslawa ^a   Ruprecht, Ruth M ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

AGE; ANIMAL; ARTICLE; DEFECTIVE VIRUS; GENE DELETION; IMMUNOLOGY; MACACA; PATHOGENICITY; REGULATOR GENE; SERODIAGNOSIS; SIMIAN IMMUNODEFICIENCY VIRUS;

AGE FACTORS; ANIMALS; ANTIBODIES, VIRAL; DEFECTIVE VIRUSES; GENE DELETION; GENES, NEF; MACACA MULATTA; NEUTRALIZATION TESTS; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 0030589259     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Desrosiers, R. C. 1990. The simian immunodeficiency viruses. Annu. Rev. Immunol. 8:557.
2. Schultz, A. M., and S.-L. Hu. 1993. Primate models for HIV vaccines. AIDS 7(Suppl. 1):S161.
3. Shafferman, A., P. B. Jahrling, R. E. Benveniste, M. G. Lewis, T. J. Phipps, F. Eden-McCutchan, J. Sadoff, C. A. Eddy, and D. S. Burke. 1991. Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type I sequences. Proc. Natl. Acad. Sci. USA 88:7126.
4. Hu, S.-L., K. Abrams, G. N. Barber, P. Moran, J. M. Zarling, A. J. Langlois, L. Kuller, W. R. Morton, and R. E. Benveniste. 1992. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255:456.
5. Clements, J. E., R. C. Montelaro, M. C. Zink, A. M. Amedee, S. Miller, A. M. Trichel, B. Jagerski, D. Hauer, L. N. Martin, R. P. Bohm, and M. Murphey-Corb. 1995. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J. Virol. 69:2737.
6. Bolognesi, D. P. 1989. HIV antibodies and vaccine design. AIDS 3(Suppl. 1): S111.
7. Weinhold, K. J., H. K. Lyerly, T. J. Matthews, D. S. Tyler, P. M. Ahearn, K. C. Stine, A. J. Langlois, D. T. Durack, and D. P. Bolognesi. 1988. Cellular antigp120 cytolytic reactivities in HIV-1 seropositive individuals. Lancet i:902.
8. Walker, B. D., S. Chakrabarti, B. Moss, T. J. Paradis, T. Flynn, A. G. Durno, R. S. Blumberg, J. C. Kaplan, M. S. Hirsch, and R. T. Schooley. 1987. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328:345.
9. Kestler, H. W., III, D. J. Ringler, K. Mori, D. L. Panacali, P. K. Sehgal, M. D. Daniel, and R. C. Desrosiers. 1991. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65:651.
10. Rud, E. W., M. Cranage, J. Yon, J. Quirk, L. Ogilvie, N. Cook, S. Webster, M. Dennis, and B. E. Clark. 1994. Molecular and biological characterisation of simian immunodeficiency virus strain 32H proviral clones containing nef size variants. J. Gen. Virol. 75:529.
11. Daniel, M. D., F. Kirchhoff, C. Czajak, P. K. Sehgal, and R. C. Desrosiers. 1992. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938.
12. Almond, N., K. Kent, M. Cranage, E. Rud, B. Clarke, and E. J. Stott. 1995. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345:1342.
13. Wyand, M. S., K. H. Manson, M. Garcia-Moll, D. C. Montefiori, and R. C. Desrosiers. 1996. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70:3724.
14. Desrosiers, R. C. 1992. HIV with multiple gene deletions as a live attenuated vaccine for AIDS. AIDS Res. Hum. Retroviruses 8:411.
15. Esparza, J. 1994. Feasibility of developing live attenuated HIV vaccines: conclusions and recommendations of the World Health Oganization Working Group. AIDS Res. Hum. Retroviruses 10:221.
16. Baba, T. W., Y. S. Jeong, D. Penninck, R. Bronson, M. F. Greene, and R. M. Ruprecht. 1995. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267:1820.
17. Baba, T. W., V. Liska, Y. Hu, R. A. Rasmussen, D. Penninck, R. Bronson, M. F. Greene, and R. M. Ruprecht 1995. Attenuated retrovirus vaccines and AIDS. Science 270:1220.
18. Ruprecht, R. M., T. W. Baba, A. R. Rasmussen, P. Sharma. 1996. Murine and simian retrovirus models: thethresholdhypothesis.AIDS. 10(Suppl. A):S33.
19. Ridge, J. P., E. J. Fuchs, and P. Matzinger. 1996. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science 271:1723.
20. Sarzotti, M., D. S. Robbins, and P. M. Hoffman. 1996. Induction of protective CTL responses in newborn mice by a murine retrovirus. Science 271:1726.
21. H2 immunity in neonatal mice. Science 271:1728.
22. Strodtbeck, F. 1995. Viral infections of the newborn. J. Obstet. Gynecol. Neonatal Nurs. 24:659.
23. Hoffman, P. M., D. S. Robbins, and H. C. Morse. 1984. Role of immunity in age-related resistance to paralysis after murine leukemia virus infection. J. Virol. 52:734.
24. Cihak, J., and F. Lehmann-Grube. 1978. Immunologic tolerance to lymphocytic choriomeningitis virus in neonatally infected virus carrier mice: evidence supporting a clonal inactivation mechanism. Immunology 34:265.
25. Wilfert, C. M., C. Wilson, K. Luzuriaga, and L. Epstein. 1994. Pathogenesis of pediatric human immunodeficiency virus type I infection. J. Infect. Dis. 170:286.
26. Lewis, M. G., S. Bellah, K. McKinnon, J. Yalley-Ogunro, P. M. Zack, W. R. Elkins, R. C. Desrosiers, and G. A. Eddy. 1994. Titration and characterization of two rhesus-derived SIVmac challenge stocks. AIDS Res. Hum. Retroviruses 10: 213.
27. Baba, T. W., J. Koch, E. S. Mittler, M. Greene, M. Wyand, D. Penninck, and R. M. Ruprecht. 1994. Mucosal infection of neonatal rhesus monkeys with cell-free SIV. AIDS Res. Hum. Retroviruses 10:351.
28. Salter, R. D., D. N. Howell, and P. Cresswell. 1985. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21:235.
29. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493.
30. Montefiori, D. C., W. E. Robinson, Jr., S. S. Schuffman, and W. M. Mitchell. 1988. Evaluation of antiviral drugs and neutralizing antibodies against human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Microbiol. 26:231.
31. Montefiori, D. C., K. A. Reimann, N. L. Letvin, J. Y. Zhou, and S.-L. Hu. 1995. Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection. AIDS Res. Hum Retroviruses 11:963.
32. Hu, S.-L., N. L. Haigwnod, and W. R. Morton. 1993. Nonhuman primate models for AIDS research. In HIV Molecular Organization, Pathogenicity and Treatment. W. J. W. Morrow and N. L. Haigwood, eds. Elsevier, Amsterdam, pp. 293-327.
33. Reimann, K. A., K. Tenner-Racz, P. Racz, D. C. Montefiori, Y. Yasutomi, W. Lin, B. J. Ransil, and N. L. Letvin. 1994. Immunopathogenic events in the acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J. Virol. 68:2362.
34. Marthas, M. L., K. K. A. Van Rompay, M. Otsyula, C. J. Miller, D. R. Canfield, N. C. Pedersen, and M. B. McChesney. 1995. Viral factors determining progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques. J. Virol. 69:4198.
35. Kannagi, M., M. Kiyotaki, R. C. Desrosiers, K. A. Reiman, N. W. King, L. M. Waldron, and N. L. Letvin. 1986. Humoral immune response to T cell tropic retrovirus simian T lymphotropic virus type III in monkeys with experimentally induced acquired immune deficiency-like syndrome. J. Clin. Invest. 78:1229.
36. Zhang, J.-Y., L. N. Martin, E. A. Watson, R. C. Montelaro, M. West, L. Epstein, and M. Murphey-Corb. 1988. Simian immunodeficiency virus/della-induced immunodeficiency disease in rhesus monkeys: relation of antibody response and antigenemia. J. Infect. Dis. 158:1277.
37. + lymphocyte responses in acutely infected rhesus monkeys. J. Virol. 67:1707.
38. Clerici, M., L. DePalma, E. Roilides, R. Baker, and G. M. Shearer. 1993. Analysis of T helper and antigen-presenting cell functions in cord blood and peripheral blood leukocytes from healthy children of different ages. J. Clin. Invest. 91:2829.
39. Pascual, M., and J. A. Schifferli. 1992, The binding of immune complexes by the erythrocyte complement receptor 1 (CR1). Immunopharmacology 24:101.
40. Montefiori, D. C. 1997. Role of complement and Fc receptors in the pathogenesis of HIV-1 infection. Springer Semin. Immunopath. In press.
41. Montefiori, D. C., B. S. Graham, J. Y. Zhou, J. T. Zhou, and J. M. Ahearn. 1994. Binding of human immunodeficiency virus type I to the C3b/C4b receptor, CR1 (CD35), and red blood cells in the presence of envelope-specific antibodies and complement. J. Infect. Dis. 170:429.
42. Davis, C. A., E. H. Vallota, and J. Forristal. 1979. Serum complement levels in infancy: age related changes. Radiat. Res. 13:1043.
43. Benveniste, O., B. Vaslin, R. Legrand, A. Cheret, F. Matheux, F. Theodora, M. P. Cranage, and D. Dormont. 1996. Comparative intmerleukin (IL)-2, interferon (IFN)-gamma and IL-4/IL-10 responses during acute infection of macaques inoculated with attenuated nef-truncated or pathogenic SIVmac251 virus. Proc. Natl. Acad. Sci. USA 93:3658.
44. Lewis, D. B., C. C. Yu, J. Meyer, B. K. English, S. J. Kahn, and C. B. Wilson. 1991. Cellular and molecular mechanisms for reduced interleukin 4 and interferon-gamma production by neonatal T cells. J. Clin. Invest. 87:194.
45. Gauduin, M.-C. G. P. Allaway, P. J. Maddon, C. F. Barbas III, D. R. Burton, and R. A. Koup. 1996. Effective ex vivo neutralization of human immunodeficiency virus type I in plasma by recombinant immunoglobulin molecules. J. Virol. 70: 2586.
46. Regier, D. A., and R. C. Desrosiers. 1990. The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res. Hum. Retroviruses 6:1221.
47. Choi, W. S., C. Collignon, C. Thiriart, D. P. W. Burns, E. J. Stott, K. A. Kent, and R. C. Desrosiers. 1994. Effects of natural sequence variation on recognition by monoclonal antibodies that neutralize simian immunodeficiency virus infectivity. J. Virol. 68:5395.
48. Sawyer, L. S. W., M. T. Wrin, L. Crawford-Miksza, B. Potts, Y. Wu, P. A. Weber, R. D. Alfonso, and C. V. Hanson. 1994. Neutralization sensitivity of human immunodeficiency virus type I is determined in part by the cell in which the virus is propagated. J. Virol. 68:1342.
49. Hanson, C. V. 1994. Measuring vaccine-induced HIV neutralization: report of a workshop. AIDS Res. Hum. Retroviruses 10:645.
50. Bou-Habib, D. C., G. Roderiquez, T. Oravecz, P. W. Herman, P. Lusso, and M. A. Norcross. 1994. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type I from antibody neutralization. J. Virol. 68:6006.
51. Montefiori, D. C., G. Pantaleo, L. M. Fink, J. T. Zhou, J. Y. Zhou, M. Bilska, G. D. Miralles, and A. S. Fauci. 1996. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type I in long term non-progressors. J. Infect. Dis. 173:60.
52. Moore, J. P., Y. Cao, L. Qing, Q. J. Sattentau, J. Pyati, R. Koduri, J. Robinson, C. F. Barbas III, D. R. Burton, and D. D. Ho. 1995. Primary isolates of human immunodeficiency virus type I are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:101.
53. Matthews, T. J. 1994. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development AIDS Res. Hum. Retroviruses 10:631.